W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01132443
Recruitment Status : Completed
First Posted : May 28, 2010
Last Update Posted : June 16, 2017
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 12, 2010
  Actual Study Completion Date : June 12, 2010
Terry M. Jones, Stacy Jasper, and Alessandra B. Alió Sáenz. Phase I study: Bioavailability of clindamycin from a new clindamycin 1% - benzoyl peroxide 3% low dose gel (DUAC 3%) . Clin Pharmacol Drug Devel. 2012;2(1):